Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Pacira BioSciences Inc (NASDAQ: PCRX) closed the day trading at $16.68 down -6.34% from the previous closing price of $17.81. In other words, the price has decreased by -$6.34 from its previous closing price. On the day, 1.42 million shares were traded. PCRX stock price reached its highest trading level at $17.94 during the session, while it also had its lowest trading level at $16.41.
Ratios:
For a better understanding of PCRX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 3.98. For the most recent quarter (mrq), Quick Ratio is recorded 1.89 and its Current Ratio is at 2.25. In the meantime, Its Debt-to-Equity ratio is 0.86 whereas as Long-Term Debt/Eq ratio is at 0.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Truist on August 13, 2024, Downgraded its rating to Sell and sets its target price to $8 from $30 previously.
On August 12, 2024, RBC Capital Mkts Downgraded its rating to Sector Perform which previously was Outperform and also lowered its target price recommendation from $37 to $14.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 13 ’24 when GAUGLER DARYL sold 500 shares for $12.86 per share. The transaction valued at 6,430 led to the insider holds 115,700 shares of the business.
GAUGLER DARYL bought 500 shares of PCRX for $6,430 on Sep 13 ’24. On Aug 16 ’24, another insider, BIGAL MARCELO, who serves as the Director of the company, bought 1,512 shares for $13.25 each. As a result, the insider paid 20,034 and bolstered with 10,142 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PCRX now has a Market Capitalization of 770168960 and an Enterprise Value of 960782656. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.11 while its Price-to-Book (P/B) ratio in mrq is 1.03. Its current Enterprise Value per Revenue stands at 1.383 whereas that against EBITDA is 5.397.
Stock Price History:
Over the past 52 weeks, PCRX has reached a high of $35.95, while it has fallen to a 52-week low of $11.16. The 50-Day Moving Average of the stock is 0.90%, while the 200-Day Moving Average is calculated to be -25.43%.
Shares Statistics:
Over the past 3-months, PCRX traded about 765.88K shares per day on average, while over the past 10 days, PCRX traded about 528160 shares per day. A total of 46.15M shares are outstanding, with a floating share count of 44.58M. Shares short for PCRX as of 1731628800 were 4822169 with a Short Ratio of 6.30, compared to 1728950400 on 6140722. Therefore, it implies a Short% of Shares Outstanding of 4822169 and a Short% of Float of 15.21.
